AdAlta strengthens funding base to advance next-generation CAR-T strategy
AdAlta Limited (ASX: 1AD) has secured binding commitments to raise approximately AU$1.2 million through an overnight strategic placement to sophisticated and professional investors, reinforcing its balance sheet and near-term execution capability. The placement was completed at AU$0.005 per share, representing a material premium to the Company’s previous capital raise and reflecting strong investor confidence following AdAlta’s recent CAR-T collaboration with Shanghai Cell Therapy Group.
Proceeds will support the advancement of BZDS1901, a first-in-class PD1-armoured MSLN CAR-T therapy targeting advanced mesothelioma, and provide flexibility to progress regulatory, development and partnering initiatives under AdAlta’s “East to West” cellular immunotherapy strategy. The Company will issue one attaching option for every two new shares, providing additional long-term funding optionality. The capital raise also strengthens AdAlta’s negotiating position as it progresses third-party financing at the AdCella subsidiary level and evaluates further licensing opportunities to expand its cellular therapy pipeline for global markets.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
AdAlta strengthens funding base to advance next-generation CAR-T strategy
AdAlta Limited (ASX: 1AD) has secured binding commitments to raise approximately AU$1.2 million through an overnight strategic placement to sophisticated and professional investors, reinforcing its balance sheet and near-term execution capability. The placement was completed at AU$0.005 per share, representing a material premium to the Company’s previous capital raise and reflecting strong investor confidence following AdAlta’s recent CAR-T collaboration with Shanghai Cell Therapy Group.
Proceeds will support the advancement of BZDS1901, a first-in-class PD1-armoured MSLN CAR-T therapy targeting advanced mesothelioma, and provide flexibility to progress regulatory, development and partnering initiatives under AdAlta’s “East to West” cellular immunotherapy strategy. The Company will issue one attaching option for every two new shares, providing additional long-term funding optionality. The capital raise also strengthens AdAlta’s negotiating position as it progresses third-party financing at the AdCella subsidiary level and evaluates further licensing opportunities to expand its cellular therapy pipeline for global markets.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au